Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01754909 · ClinicalTrials.gov registry record · Phase 2
Mitigation of Radiation Pneumonitis and Fibrosis
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT01754909: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT01754909 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01754909, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This project will test the effect of enalapril to mitigate the lung damage that can occur as a side effect of radiation therapy for lung cancer or other intrathoracic cancers. Thousands of Veterans develop lung cancer every year, and are treated by radiation therapy. Studies of lung radiation injury in laboratory animals show that with enalapril, investigators can significantly reduce the severity of radiation injury to the lung. Enalapril is FDA approved and in common use for treatment of hypertension, kidney disease, and heart failure. These studies will advance that work to human use. Successful mitigation of lung radiation damage will improve the quality of life in Veterans and non-Veterans who are treated for lung cancer by radiation, and may also improve cure rates of radiation therapy for lung cancer.
Interventions
- DRUG placebo
- DRUG Enalapril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2013-11-01 |
| Est. Completion | 2018-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01754909
The ClinicalTrials.gov registry entry for NCT01754909 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01754909 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01754909 about?
NCT01754909 is a clinical study titled "Mitigation of Radiation Pneumonitis and Fibrosis". This project will test the effect of enalapril to mitigate the lung damage that can occur as a side effect of radiation therapy for lung cancer or other intrathoracic cancers. Thousands of Veterans develop lung cancer every year, and are treated by radiation therapy. Studies of lung radiation injury...
What is the current status of trial NCT01754909?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2013-11-01. Estimated completion is 2018-04-01.
What interventions are being tested in trial NCT01754909?
The interventions under investigation include: placebo (DRUG), Enalapril (DRUG).
Who is sponsoring clinical trial NCT01754909?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.